Date: 2015-03-02
Type of information: Private placement
Company: Xencor (USA - CA)
Investors:
Amount: $122.9 million
Funding type: private placement
Planned used: Xencor anticipates using the net proceeds from the offering for general corporate purposes, which may include clinical development of its lead drug candidates, product candidate discovery, technology development, patent prosecution activities, working capital and other general corporate purposes.
Others: * On March 2, 2015, Xencor announced the completion of an underwritten public offering of 8,625,000 shares of its common stock, including 1,125,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Xencor at a price to the public of $14.25 per share. The gross proceeds to Xencor from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xencor, were approximately $122.9 million. * On February 23, 2015, Xencor announced that it intends to offer and sell, subject to market and other conditions, up to 5,500,000 shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock offered in the public offering. All of the shares are being offered by Xencor. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Leerink Partners acted as sole book-running manager in the offering. Wedbush PacGrow Life Sciences and Oppenheimer & Co. acted as co-managers in the offering.
* On February 25, 2015, Xencor announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock, offered at a price to the public of $14.25 per share. The gross proceeds from this offering to Xencor are expected to be $106.9 million, before deducting underwriting discounts and commissions and offering expenses payable by Xencor. The offering is expected to close on or about March 2, 2015, subject to customary closing conditions. In addition, Xencor has granted the underwriters a 30-day option to purchase up to an aggregate of 1,125,000 additional shares of common stock. All of the shares are being offered by Xencor. Xencor expects to use net proceeds of this offering for general corporate purposes, which may include clinical development of its lead drug candidates, product candidate discovery, technology development, patent prosecution activities, working capital and other general corporate purposes.
Therapeutic area: Allergic diseases - Autoimmune diseases - Respiratory diseases - Cancer - Oncology
